is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
We have analyzed brain and acute leukemia, cytoplasmic () gene expression and other genetic markers (, , , , , , and mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low expressers...
Saved in:
Published in | Annals of hematology Vol. 89; no. 5; pp. 453 - 458 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Springer Verlag
27.11.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | We have analyzed brain and acute leukemia, cytoplasmic () gene expression and other genetic markers (, , , , , , and mutations) in 127 intermediate-risk acute myeloid leukemia (AML) patients: 98 cytogenetically normal and 29 with intermediate-risk cytogenetic alterations. High versus low expressers showed a higher refractoriness to induction treatment (31% vs 10%; = .005), lower complete remission rate after salvage therapy (82% vs 97%; = .010), and lower 3-year overall (23% vs 58%, < .001) and relapse-free survival (26% vs 52%, = .006). Similar results were found when cytogenetic subgroups were analyzed separately. Multivariate models confirmed the unfavorable prognosis of this marker. In conclusion, is a relevant prognostic marker in intermediate-risk AML. |
---|---|
ISSN: | 0939-5555 1432-0584 |
DOI: | 10.1007/s00277-009-0864-x |